Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Article Details
- CitationCopy to clipboard
Zhao XJ, Ishizaki T
Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Br J Clin Pharmacol. 1997 Nov;44(5):505-11.
- PubMed ID
- 9384469 [ View in PubMed]
- Abstract
AIMS: Nine antimalarial (plus two metabolites of proguanil) and twelve non-antimalarial drugs were tested for their possible interaction with CYP3A4-catalysed 3-hydroxylation of quinine by human liver microsomes in vitro. METHODS: 3-Hydroxyquinine was assayed in the incubation mixture by an h.p.l.c. method using fluorometric detection. The respective IC50 values were estimated for the twenty-one drugs and two metabolites of proguanil tested herein. RESULTS: Thirteen drugs exhibited an inhibitory effect on the 3-hydroxylation of quinine. According to the respective mean IC50 values, the inhibitory rank order of the drugs was: ketoconazole > troleandomycin (TAO, with preincubation) > doxycycline > omeprazole > primaquine > tetracycline = TAO (without preincubation) > nifedipine > erythromycin > verapamil > cimetidine > diltiazem > oleandomycin > hydralazine. Other drugs or metabolites showed little or no inhibition of quinine metabolism (mean IC50 > 200 or 500 microM). Among the antimalarial drugs, doxycycline showed relatively potent inhibition of quinine 3-hydroxylation with a mean IC50 value of 17 microM, followed by primaquine and tetracycline, with mean IC50 values of 20 and 29 microM, respectively. CONCLUSIONS: When the plasma/serum concentrations possibly attained after their usual therapeutic doses were taken into account, tetracycline, doxycycline, omeprazole, ketoconazole, nifedipine, TAO and erythromycin are likely to be inhibitors of quinine metabolism in patients when the drugs are co-administrated with quinine.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Hydralazine Cytochrome P450 3A4 Protein Humans NoInhibitorDetails Primaquine Cytochrome P450 3A4 Protein Humans UnknownSubstrateInhibitorDetails Tetracycline Cytochrome P450 3A4 Protein Humans UnknownSubstrateInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareAmodiaquineVemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amodiaquine. ArtemetherVemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemether. ArtemotilVemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemotil. ArtenimolVemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artenimol. ArtesunateVemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artesunate.